Invitae Corporation (NYSE:NVTA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Invitae Corp Exhibit
EX-99.1 2 d745606dex991.htm EX-99.1 EX-99.1 Exhibit 99.1     Invitae to Acquire Jungla to Advance Genetic Variant Interpretation,…
To view the full exhibit click here

About Invitae Corporation (NYSE:NVTA)

Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company offers panels for over 120 conditions in hereditary cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. It has developed an offering that enables healthcare professionals to customize a test and receive test results at requisition.